Tags : India

Biosimilars

Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

Shots: The company received DCGI’s MA for Teriparatide (biosimilar) for the treatment of Osteoporosis vs anti-resorptive therapies such as bisphosphates and SERMs The approved product will be marketed through Alkem Laboratories as well as it explore other potential partnering opportunities Teriparatide will be launched in a fully compliant pen device Click here ­to­ read full press […]Read More

Viewpoints

ViewPoints Article: Digital Healthcare in India – Current Trends &

Digital healthcare means using communications and information technologies in medicine to diagnose, predict, treat, and monitor diseases. It is also widely used for prognosis, rehabilitation, behavioral health, and public health.  Indians have witnessed a surge of smartphone and internet use since the last decade. This had led to an easier delivery of smart digital solutions. […]Read More

Biotech

Sanofi Launches Tetraxim (DTaP-IPV) for Preschoolers in India

Shots: Sanofi’s Tetraxim combines four vaccines into one and provides protection against four diseases – Diphtheria, Pertussis, Tetanus and Polio. The launch reduces the number of injections, increases comfort, and improves vaccination compliance for children Booster vaccines are designed to boost the immunity acquired during prior vaccination. With the launch, Sanofi currently protects school children […]Read More

Viewpoints

ViewPoints Article: COVID-19 Treatment in India and Abroad

In late 2019, a mysterious virus causing infection consisting of dry cough, fever tiredness, and last pneumonia first appeared in Wuhan, China. The world health organization (WHO) named the disease as Coronavirus 2019 (Covid-19). Interestingly, Covid-19 and flu (caused by influenza virus) share the common disease progression asymptomatic (no symptoms), mild symptoms fever or chills, […]Read More

Biosimilars

Cadila Launches Cadalimab (biosimilar, adalimumab) in India

Shots: Cadila has launched the adalimumab biosimilar under the brand name Cadalimab, referencing AbbVie’s Humira which is used to treat RA,PsA, AS and psoriasis The launch strengthens Cadila’s biosimilar portfolio as Cadalimab is the fourth biosimilar launched in the last 2mos. following Bevaro, Ritucad and NuPTH for cancer and osteoporosis Cadalimab is available in 40mg/0.8ml, […]Read More

Biosimilars Regulatory

Cadila to Launch its Cadalimab (biosimilar, adalimumab) in India

Shots: Cadalimab will be available in 40mg/0.8ml as a pre-filled syringe and is targeted for the reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Psoriasis Additionally, Cadila has launched 3 more biosimilar products Bevaro, Ritucad, and NuPTH in the last 2 months Adalimumab is a mAb and […]Read More